PT1272161E - Sistemas de distribuição de fármacos à base de lípidos que contêm derivados lipídicos degradáveis da fosfolipase a2 para utilização clínica contra infecções parasitárias - Google Patents

Sistemas de distribuição de fármacos à base de lípidos que contêm derivados lipídicos degradáveis da fosfolipase a2 para utilização clínica contra infecções parasitárias Download PDF

Info

Publication number
PT1272161E
PT1272161E PT01921262T PT01921262T PT1272161E PT 1272161 E PT1272161 E PT 1272161E PT 01921262 T PT01921262 T PT 01921262T PT 01921262 T PT01921262 T PT 01921262T PT 1272161 E PT1272161 E PT 1272161E
Authority
PT
Portugal
Prior art keywords
lipid
drug delivery
delivery systems
based drug
parasitic infections
Prior art date
Application number
PT01921262T
Other languages
English (en)
Inventor
Kent Jorgensen
Jesper Davidsen
Ole G Mouritsen
Charlotte Vermehren
Sven Frokjaer
Original Assignee
Liplasome Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma As filed Critical Liplasome Pharma As
Publication of PT1272161E publication Critical patent/PT1272161E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PT01921262T 2000-04-12 2001-04-11 Sistemas de distribuição de fármacos à base de lípidos que contêm derivados lipídicos degradáveis da fosfolipase a2 para utilização clínica contra infecções parasitárias PT1272161E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200000616 2000-04-12

Publications (1)

Publication Number Publication Date
PT1272161E true PT1272161E (pt) 2008-02-08

Family

ID=8159422

Family Applications (3)

Application Number Title Priority Date Filing Date
PT01921262T PT1272161E (pt) 2000-04-12 2001-04-11 Sistemas de distribuição de fármacos à base de lípidos que contêm derivados lipídicos degradáveis da fosfolipase a2 para utilização clínica contra infecções parasitárias
PT01921261T PT1272160E (pt) 2000-04-12 2001-04-11 Sistemas de distribuição de fármacos com base lipídica para aplicação tópica.
PT01921263T PT1272225E (pt) 2000-04-12 2001-04-11 Sistema à base de lípidos para orientação de agentes de diagnóstico

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT01921261T PT1272160E (pt) 2000-04-12 2001-04-11 Sistemas de distribuição de fármacos com base lipídica para aplicação tópica.
PT01921263T PT1272225E (pt) 2000-04-12 2001-04-11 Sistema à base de lípidos para orientação de agentes de diagnóstico

Country Status (11)

Country Link
US (4) US7166297B2 (pt)
EP (3) EP1272160B1 (pt)
JP (3) JP2003530338A (pt)
AT (2) ATE382333T1 (pt)
AU (3) AU2001248302A1 (pt)
CY (2) CY1105792T1 (pt)
DE (3) DE60132184T2 (pt)
DK (3) DK1272225T3 (pt)
ES (3) ES2280355T3 (pt)
PT (3) PT1272161E (pt)
WO (3) WO2001076644A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
WO2002085391A1 (es) * 2001-04-24 2002-10-31 Luis Alberto Costa Uso de una fosfolipasa a2 para la preparacion de composiciones farmaceuticas y/o cosmeticas para la prevencion y/o el tratamiento local y/o sistemico de enfermedades y/o procesos provocados por patogenos intra y extracelulares que expresen fosfolipidos de membrana
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005016141A1 (en) * 2003-07-09 2005-02-24 California Pacific Medical Center Remote detection of substance delivery to cells
US20050266066A1 (en) * 2003-10-20 2005-12-01 Nof Corporation Phospholipid membrane preparation
WO2005077963A1 (fr) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais DErivEs de saccharides et d'itols possEdant un groupement O-alkyle ou un groupement O-alkyle et un groupement O-n-butanoyle. Applications comme mEdicaments dans les pathologies prolifEratives tumorales ou bEnignes.
US20080113014A1 (en) * 2004-01-28 2008-05-15 Ltt Bio-Pharma Co., Ltd. Method for Screening for Compounds Safe for Gastric Mucosa
DE102004010387A1 (de) * 2004-03-03 2005-09-22 Siemens Ag Kontrastmittel für die Röntgen-Computertomographie
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20070065359A1 (en) * 2005-03-14 2007-03-22 Shiladitya Sengupta Nanocells for diagnosis and treatment of diseases and disorders
PL1933809T3 (pl) * 2005-10-11 2012-09-28 Yissum Research Development Company Of The Hebrew Univ Of Jerusalem Kompozycje do dostarczania donosowego
JP2009520730A (ja) * 2005-12-23 2009-05-28 ヤド・テヒノロギース・ゲーエムベーハー アレルギー性疾患を治療および予防するための手段および方法
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
BR112012003834A2 (pt) 2009-08-21 2017-08-08 Targeted Delivery Tech Limited métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011102904A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion therapeutic delivery system
WO2011102906A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion delivery system
WO2011102905A1 (en) * 2010-02-19 2011-08-25 Robert Shorr Imageable lipid-oil-water nanoemulsion diagnostic delivery system
WO2013131164A1 (pt) * 2012-03-09 2013-09-12 Universidade Federal De Minas Gerais - Ufmg Composição farmacêutica contendo lipossomas convencionais e lipossomas de circulação prolongada para o tratamento da leishmaniose visceral
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
WO2014047116A1 (en) * 2012-09-18 2014-03-27 Comfort Care For Animals Llc Encapsulating liposomes
EP3954361A1 (en) 2015-06-30 2022-02-16 Sequessome Technology Holdings Limited Multiphasic compositions
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0714865B2 (ja) * 1986-10-28 1995-02-22 武田薬品工業株式会社 リポソ−ム製剤およびその製造法
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
FR2638639A1 (fr) * 1988-11-08 1990-05-11 Parincos Parfumerie Cosmet Int Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US4874794A (en) * 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
JPH0370491A (ja) 1989-08-04 1991-03-26 Toshiba Corp 電動機制御装置
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US5827836A (en) * 1996-11-15 1998-10-27 Clarion Pharmaceuticals Inc. Retinoid glycerol phospholipid conjugates
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof

Also Published As

Publication number Publication date
DE60126072T2 (de) 2007-11-08
DE60122304D1 (de) 2006-09-28
EP1272160A2 (en) 2003-01-08
WO2001076556A2 (en) 2001-10-18
JP2003530339A (ja) 2003-10-14
US7166297B2 (en) 2007-01-23
ES2280355T3 (es) 2007-09-16
US20030162748A1 (en) 2003-08-28
PT1272160E (pt) 2007-04-30
ATE382333T1 (de) 2008-01-15
EP1272161A2 (en) 2003-01-08
CY1105792T1 (el) 2011-02-02
DK1272225T3 (da) 2006-12-27
WO2001076555A3 (en) 2002-03-14
WO2001076644A2 (en) 2001-10-18
DK1272160T3 (da) 2007-05-21
AU2001248301A1 (en) 2001-10-23
PT1272225E (pt) 2007-01-31
WO2001076644A3 (en) 2002-03-14
AU2001248302A1 (en) 2001-10-23
ES2295149T3 (es) 2008-04-16
CY1106462T1 (el) 2012-01-25
AU2001248303A1 (en) 2001-10-23
DE60126072D1 (de) 2007-03-08
DK1272161T3 (da) 2008-05-19
EP1272160B1 (en) 2007-01-17
DE60122304T2 (de) 2007-08-09
ATE336267T1 (de) 2006-09-15
DE60132184D1 (de) 2008-02-14
JP2003530362A (ja) 2003-10-14
EP1272225A2 (en) 2003-01-08
US7368254B2 (en) 2008-05-06
ES2270991T3 (es) 2007-04-16
JP2003530338A (ja) 2003-10-14
US20030175205A1 (en) 2003-09-18
WO2001076556A3 (en) 2002-07-11
US20070134153A1 (en) 2007-06-14
EP1272225B1 (en) 2006-08-16
EP1272161B1 (en) 2008-01-02
DE60132184T2 (de) 2009-01-15
WO2001076555A2 (en) 2001-10-18
US20030170297A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
PT1272161E (pt) Sistemas de distribuição de fármacos à base de lípidos que contêm derivados lipídicos degradáveis da fosfolipase a2 para utilização clínica contra infecções parasitárias
AU6185398A (en) Charged lipids and uses for the same
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
CA2263203A1 (en) 3,6-ketal and enol ether macrolide antibiotics
GB0222495D0 (en) Compounds
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
ES2180274T3 (es) Disoluciones nasales.
TW200626608A (en) Macrolides
DE60038252D1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
TW200611695A (en) Pyrrolopyridine derivatives
NO20031323L (no) Peptid-baserte forbindelser
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
GT200000035AA (es) Derivados de resorcinol, (solicitud fraccionaria no. 1 derivada de la patente pi-2000-0035)
BR9911885A (pt) Inibidores da angiogênese
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
BR0011845A (pt) Complexo farmacêutico
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
WO2005039480A3 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
NO20056089L (no) Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner
DE60235549D1 (de) Pharmazeutische formulierung und darin enthaltende liganden; uea-1 mimetika
HUP0202888A2 (hu) Xenogén oligo- és/vagy poliribonukleotidokat tartalmazó gyógyszerkészítmény
BR0212274A (pt) Uso de estrogênios não-feminilizantes como agentes retinoprotetores para o tratamento de glaucoma
DK1257538T3 (da) 9-alkylamino-1-nitroacridin-derivater
SE9902674D0 (sv) New composition
EA200500903A1 (ru) Силиловые простые эфиры